EP Patent

EP1667986A1 — Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Assigned to Aventis Pharma SA · Expires 2006-06-14 · 20y expired

What this patent protects

Solvat acétonique du diméthoxy docétaxel ou (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phényl- propionate de 4-acétoxy-2alpha-benzoyloxy-5beta,20-époxy-1-hydroxy-7beta,10beta-diméthoxy-9- oxo-tax-11-ène-13alpha-yle et sa préparation par cristallisation à partir d'une solution…

USPTO Abstract

Solvat acétonique du diméthoxy docétaxel ou (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phényl- propionate de 4-acétoxy-2alpha-benzoyloxy-5beta,20-époxy-1-hydroxy-7beta,10beta-diméthoxy-9- oxo-tax-11-ène-13alpha-yle et sa préparation par cristallisation à partir d'une solution hydro-acétonique.

Drugs covered by this patent

Patent Metadata

Patent number
EP1667986A1
Jurisdiction
EP
Classification
—
Expires
2006-06-14
Drug substance claim
No
Drug product claim
No
Assignee
Aventis Pharma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.